|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,824.50 GBX | +0.19% |
|
+1.08% | +35.50% |
| 12-12 | US FDA approves Innoviva's oral antibiotic for gonorrhea | RE |
| 12-12 | Surprise UK GDP Contraction Keeps FTSE 100 in the Red | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 6.29B | 4.27B | 3.72B | 2.94B | 3.87B | |||||
Short Term Investments | 480M | 614M | 750M | 450M | 381M | |||||
Trading Asset Securities, Total | 63M | 77M | 4.25B | 2.3B | 75M | |||||
Total Cash And Short Term Investments | 6.84B | 4.96B | 8.72B | 5.69B | 4.33B | |||||
Accounts Receivable, Total | 5.55B | 6.25B | 5.45B | 5.9B | 5.56B | |||||
Other Receivables | 1.3B | 1.21B | 969M | 1.08B | 1B | |||||
Notes Receivable | 11M | 18M | 11M | 9M | 7M | |||||
Total Receivables | 6.86B | 7.48B | 6.43B | 7B | 6.58B | |||||
Inventory | 6B | 5.78B | 5.15B | 5.5B | 5.67B | |||||
Prepaid Expenses | 359M | 315M | 343M | 355M | 390M | |||||
Other Current Assets, Total | 195M | 133M | 123M | 108M | 37M | |||||
Total Current Assets | 20.25B | 18.67B | 20.77B | 18.64B | 17B | |||||
Gross Property Plant And Equipment | 21.46B | 20.7B | 19.36B | 19.59B | 19.92B | |||||
Accumulated Depreciation | -10.45B | -10.02B | -9.74B | -9.63B | -9.84B | |||||
Net Property Plant And Equipment | 11.01B | 10.67B | 9.62B | 9.96B | 10.07B | |||||
Long-term Investments | 3.5B | 2.28B | 1.58B | 1.22B | 1.23B | |||||
Goodwill | 10.6B | 10.55B | 7.05B | 6.81B | 6.98B | |||||
Other Intangibles, Total | 29.82B | 30.08B | 14.32B | 14.77B | 15.52B | |||||
Deferred Tax Assets Long-Term | 4.29B | 5.22B | 5.66B | 6.05B | 6.76B | |||||
Other Long-Term Assets, Total | 974M | 1.63B | 1.16B | 1.56B | 1.91B | |||||
Total Assets | 80.43B | 79.1B | 60.15B | 59B | 59.46B | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 4.36B | 4.54B | 3.87B | 3.72B | 3.46B | |||||
Accrued Expenses, Total | 8.73B | 9.97B | 4.04B | 4.08B | 4.06B | |||||
Short-term Borrowings | 1.05B | 707M | 1.49B | 893M | - | |||||
Current Portion of Long-Term Debt | 2.45B | 2.69B | 2.3B | 1.76B | 2.18B | |||||
Current Portion of Leases | 230M | 203M | 167M | 156M | 168M | |||||
Current Income Taxes Payable | 545M | 489M | 471M | 500M | 703M | |||||
Unearned Revenue Current, Total | 361M | 307M | 299M | 222M | 171M | |||||
Other Current Liabilities | 4.43B | 4.76B | 10.19B | 9.73B | 10.95B | |||||
Total Current Liabilities | 22.15B | 23.67B | 22.81B | 21.07B | 21.7B | |||||
Long-Term Debt | 22.54B | 19.76B | 16.19B | 14.15B | 13.7B | |||||
Long-Term Leases | 887M | 812M | 841M | 1.05B | 934M | |||||
Unearned Revenue Non Current | 21M | 85M | 83M | 254M | 165M | |||||
Pension & Other Post Retirement Benefits | 3.65B | 3.11B | 2.58B | 2.34B | 1.86B | |||||
Deferred Tax Liability Non Current | 3.6B | 3.56B | 289M | 311M | 382M | |||||
Other Non Current Liabilities | 6.78B | 6.76B | 7.25B | 7.03B | 7.63B | |||||
Total Liabilities | 59.62B | 57.76B | 50.05B | 46.21B | 46.38B | |||||
Common Stock, Total | 1.35B | 1.35B | 1.35B | 1.35B | 1.35B | |||||
Additional Paid In Capital | 3.28B | 3.3B | 3.44B | 3.45B | 3.47B | |||||
Retained Earnings | 7.29B | 8.75B | 4.79B | 7.74B | 8.77B | |||||
Comprehensive Income and Other | 2.67B | 1.66B | 1.02B | 805M | 83M | |||||
Total Common Equity | 14.59B | 15.06B | 10.6B | 13.35B | 13.67B | |||||
Minority Interest | 6.22B | 6.29B | -502M | -552M | -585M | |||||
Total Equity | 20.81B | 21.34B | 10.1B | 12.8B | 13.09B | |||||
Total Liabilities And Equity | 80.43B | 79.1B | 60.15B | 59B | 59.46B | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 3.98B | 4.01B | 4.03B | 4.06B | 4.08B | |||||
ECS Total Common Shares Outstanding | 3.98B | 4.01B | 4.03B | 4.06B | 4.08B | |||||
Book Value / Share | 3.66 | 3.76 | 2.63 | 3.29 | 3.35 | |||||
Tangible Book Value | -25.83B | -25.58B | -10.77B | -8.23B | -8.83B | |||||
Tangible Book Value Per Share | -6.48 | -6.38 | -2.67 | -2.03 | -2.16 | |||||
Total Debt | 27.15B | 24.17B | 20.99B | 18.02B | 16.99B | |||||
Net Debt | 20.32B | 19.21B | 12.26B | 12.33B | 12.66B | |||||
Debt Equivalent of Unfunded Proj. Benefit Obligation | 2.1B | 1.13B | 1.36B | 763M | 103M | |||||
Debt Equivalent Oper. Leases | 216M | 160M | 136M | 216M | 240M | |||||
Minority Interest, Total (Incl. Fin. Div) | 6.22B | 6.29B | -502M | -552M | -585M | |||||
Equity Method Investments, Total | 364M | 88M | 74M | 55M | 96M | |||||
Account Code - Inventory Valuation | 5 | 5 | 5 | 5 | 5 | |||||
Inventories - Raw Materials, Total | 1.17B | 1.77B | 1.58B | 1.59B | 1.36B | |||||
Inventories - Work In Process, Total | 2.4B | 1.89B | 2.29B | 2.45B | 2.68B | |||||
Inventories - Finished Goods, Total | 2.43B | 2.12B | 1.28B | 1.46B | 1.62B | |||||
Land - (BS) | 7.21B | 6.95B | 6.39B | 6.22B | 6.12B | |||||
Machinery, Total | 11.55B | 11.3B | 10.48B | 10.34B | 10.64B | |||||
Full Time Employees | 94.07K | 90.1K | 69.4K | 70.21K | 68.63K | |||||
Assets under Capital Lease - Gross | - | - | - | - | - | |||||
Assets under Capital Lease - Accumulated Depreciation | - | - | - | - | - | |||||
Accumulated Allowance for Doubtful Accounts (Supple) | 151M | 150M | 91M | 85M | 99M |
- Stock Market
- Equities
- GSK Stock
- Financials GSK plc
- Balance Sheet
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















